title: Effects of 100 and 300 units of onabotulinum toxin A on lower urinary tract symptoms of benign prostatic hyperplasia: a phase II randomized clinical trial.
abstract: OBJECTIVE
  We conducted a 2-stage, multicenter, double-blind, randomized phase II clinical trial of 100 and 300 unit doses of onabotulinum toxin A to treat the lower urinary tract symptoms of benign prostatic hyperplasia.
  
  
  METHODS
  Men 50 years old or older with clinically diagnosed benign prostatic hyperplasia, American Urological Association symptom index 8 or greater, maximum urinary flow rate less than 15 ml per second, voided volume 125 ml or greater, and post-void residual 350 ml or less were randomized to prostatic transrectal injection of 100 or 300 units of onabotulinum toxin A. The primary outcome was at least 30% improvement from baseline to 3 months in American Urological Association symptom index and/or maximum urinary flow rate and safety. The men were followed for 12 months.
  
  
  RESULTS
  A total of 134 men were randomized and treated (68 with 100 units, 66 with 300 units), with 131 assessed at 3 months and 108 assessed at 12 months. Each dose met the 3-month primary outcome criteria. In the 100 unit arm the mean baseline American Urological Association symptom index of 18.8 decreased by 7.1 and 6.9 at 3 and 12 months, respectively. In the 300 unit arm the baseline of 19.5 decreased by 8.9 and 7.1, respectively. In the 100 unit arm the mean baseline maximum urinary flow rate of 10.0 ml per second increased by 2.5 and 2.2, respectively, and in the 300 unit arm the baseline of 9.6 increased by 2.6 and 2.3, respectively.
  
  
  CONCLUSIONS
  The intraprostatic injection of 100 or 300 units of onabotulinum toxin A passed predetermined criteria for treatment efficacy and safety, and a randomized trial with either dose is warranted. The 100 unit dose may be preferable due to similar efficacy with reduced costs and adverse effects.
authors.affiliation: Section of Urologic Oncology, School of Medicine, University of Colorado Denver, Aurora, Colorado, USA.
authors.forename: E David
authors.initials: ED
authors.lastname: Crawford
authors.forename: Kathryn
authors.initials: K
authors.lastname: Hirst
authors.forename: John W
authors.initials: JW
authors.lastname: Kusek
authors.forename: Robert F
authors.initials: RF
authors.lastname: Donnell
authors.forename: Steven A
authors.initials: SA
authors.lastname: Kaplan
authors.forename: Kevin T
authors.initials: KT
authors.lastname: McVary
authors.forename: Lance A
authors.initials: LA
authors.lastname: Mynderse
authors.forename: Claus G
authors.initials: CG
authors.lastname: Roehrborn
authors.forename: Christopher P
authors.initials: CP
authors.lastname: Smith
authors.forename: Reginald
authors.initials: R
authors.lastname: Bruskewitz
mesh_terms: D000368:Aged; D019274:Botulinum Toxins, Type A / Q000008:administration & dosage*; D004311:Double-Blind Method; D006801:Humans; D008297:Male; D009465:Neuromuscular Agents / Q000008:administration & dosage*; D011470:Prostatic Hyperplasia / Q000150:complications*; D053448:Prostatism / Q000188:drug therapy* / Q000209:etiology*; D014555:Urination Disorders / Q000188:drug therapy* / Q000209:etiology*
chemical_list: D009465:Neuromuscular Agents; D019274:Botulinum Toxins, Type A